Lauren Kaskiel

Chief Business Officer

Lauren Kaskiel MBA

Chief Business Officer

Lauren has more than 20 years of experience in the biotech and pharmaceutical industry. Prior to joining AAVantgarde, Lauren was Chief Business Officer at Code Biotherapeutics where she oversaw business and corporate development, alliance management, investor relations and intellectual property functions and was responsible for Code Bio’s strategic licenses and collaborations including therapeutic and technical opportunity evaluation for both internal and external pipeline expansion.

Prior to Code, she served as Chief of Staff to the CEO and Corporate Management Team and Head of Program and Alliance Management at Spark Therapeutics. During her time at Spark, Lauren served as a liaison with the Roche Group to support engagement and interactions during the acquisition of Spark in 2019. Lauren also held roles in New Product Planning and Program Management, establishing and managing key strategic relationships on gene therapy programs with Pfizer and Novartis.

Previously, Lauren was at GlaxoSmithKline (GSK) in research, operations, strategy, and alliance management roles. As part of GSK’s Worldwide Business Development team, Lauren managed over 20 alliances with biotech, diagnostic and venture partners.